Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could (...)
Site référencé: The Economic Times
The Economic Times
Will US Fed rate cut lead to revival of foreign investment in Indian stocks
19/09/2025
Nifty, Sensex rise for a 3rd day after US Fed rate cut
19/09/2025
After 4 days of gains, rupee closes 32 paise lower at 88.13
19/09/2025
Accelerate asset monetisation in railways, roads : Sebi chief Tuhin Kanta Pandey
18/09/2025
Smallcap multibagger defence stock surges 20% after Rs 95-crore BrahMos order win
18/09/2025
GE Healthcare exploring stake sale in China unit, says reports
18/09/2025
